In primary prostate cancer, a relatively low incidence (10–20%) of p53 gene mutations has been described, however, in advanced stages of the disease, the p53 is mutated in 42% of the cases and it is associated with bone metastases and androgen-independent disease [34], [35]. Here, TP53 is linked to prostate cancer.